Who wouldn’t want the possibility
of long-term survival?
In a clinical trial, median* overall survival among patients receiving YERVOY® (ipilimumab) was 10 months. Treatment with YERVOY decreased the risk of death by about one-third compared to patients who received the experimental drug.
*The median is the middle point at which half of the patients were still alive.
YERVOY clinical trial results
Will YERVOY work for you? Whether you’re just researching your options, or your doctor has prescribed YERVOY for you, that’s probably the first question you’ll have. The truth is, there are no sure things in metastatic melanoma treatment. And no one, not even your oncologist, can tell you ahead of time if a specific drug will or won’t work for you as an individual.
But you can see how YERVOY worked for the metastatic melanoma patients in the YERVOY clinical trial. A drug—a treatment—gets approved by the FDA based on the documented clinical trial results.
You want more than hope. With YERVOY, you have evidence
Here’s a summary of the metastatic melanoma clinical trials for YERVOY. Take a good look—then take that knowledge with you to your next appointment. It can help you have a more detailed conversation with your doctor.
In the YERVOY clinical trial, unresectable or metastatic melanoma patients were previously treated with one or more of the following: aldesleukin, dacarbazine, temozolomide, fotemustine, or carboplatin.
Clinical trial results have shown that some YERVOY patients lived substantially longer than patients who did not receive YERVOY.
YERVOY will not work for every patient. Individual results will vary. It is important to ask your doctor if YERVOY is right for you.
How were patients treated in the YERVOY clinical trials?
Of the 676 patients with unresectable or metastatic melanoma that participated in this trial: 20% (137 patients) received YERVOY alone, another 20% (136 patients) received another experimental drug alone, and 60% (403 patients) received YERVOY along with the experimental drug.
What was the goal of the YERVOY study?
The major goal was to measure how long patients lived with YERVOY in combination with the experimental drug compared to the experimental drug alone.
What were the results of the study?
Patients who received YERVOY alone and patients who took YERVOY plus another experimental drug showed a median* overall survival of 10 months. Patients who took the experimental drug alone showed a median overall survival of 6 months.
Over the course of the study, treatment with YERVOY decreased the risk of death by about one third compared to patients who received the experimental drug.
Based on the published results of this study, it is estimated that:
46% of patients taking YERVOY alone were alive at year 1.
Estimated percentage, compared with 25% of patients taking an experimental drug alone.
24% of patients taking YERVOY alone were alive at year 2.
Estimated percentage, compared with 14% of patients taking an experimental drug alone.
What are the serious side effects of YERVOY?
YERVOY can cause serious side effects in many parts of the body which can lead to death. The serious side effects of YERVOY may include: inflammation of the intestines (colitis) that can cause tears or holes (perforation) in the intestines; inflammation of the liver (hepatitis) that can lead to liver failure; inflammation of the skin that can lead to severe skin reaction (toxic epidermal necrolysis); inflammation of the nerves that can lead to paralysis; inflammation of hormone glands (especially the pituitary, adrenal, and thyroid glands) that may affect how these glands work; and inflammation of the eyes.
What are the most common side effects of YERVOY?
The most common side effects of YERVOY are tiredness, diarrhea, itching, and rash.
When could side effects appear?
Side effects are most likely to begin during treatment; however, they can appear months after your last infusion.
What should I do if I experience side effects?
Call your healthcare provider if you have any signs or symptoms, or if they get worse. Even seemingly mild symptoms can lead to severe or even life-threatening conditions if not addressed.
Do not try to treat symptoms yourself. Your healthcare provider should perform blood tests, such as liver and thyroid function tests, before starting and during treatment with YERVOY. Your oncologist may decide to delay or stop YERVOY.
These are not all of the possible side effects of YERVOY. Please see Medication Guide for additional information. If you have any questions about your health or medicines, talk to your healthcare provider.